Topic: Metastatic Bladder Cancer

Bladder Cancer Journal Vol. 6, Issue 4

Upregulated FGFR3 signaling in NMIBC and MIBC, the diagnosis and management of checkpoint inhibitor side effects in bladder cancer patients, the etiology of treatment delays in patients receiving neoadjuvant chemotherapy for MIBC, and 25-year trends in stage-specific incidence rates for bladder cancer.

Read More

Updates on Immunotherapy for Bladder Cancer

Daniel P. Petrylak, MD, discusses new treatments for metastatic bladder cancer and the importance of accurate PD-L1 markers. He also offers his predictions for bladder cancer checkpoint inhibitor therapy and second-line agents for patients who do not respond to checkpoint inhibitors.

Read More

New Targets for Advanced Bladder Cancer

Daniel P. Petrylak, MD, discusses the efficacy of checkpoint inhibitors in previously cisplatin treated metastatic urothelial carcinoma patients and the need for better biomarkers for checkpoint proteins. He also identifies future directions for treating the disease, including ipilimumab/nivolumab and epacadostat/ pembrolizumab combinations, and PD-L1 immunohistochemical staining.

Read More
Loading

Join the GRU Community

- Why Join? -